Clinical Guideline To Manage GSM in Women With Breast Cancer

by Sushma Rao on  May 18, 2018 at 10:21 AM Women Health News
RSS Email Print This Page Comment bookmark
Font : A-A+

The North American Menopause Society (NAMS) and The International Society for the Study of Women's Sexual Health (ISSWSH) have together formed a multidisciplinary Consensus Panel to develop a new guideline for clinicians to manage genitourinary syndrome of menopause (GSM) in women with or at high risk for breast cancer. GSM is often prevalent in women survivors of breast cancer survivors, as compared to other menopausal women, and commonly left undiagnosed and untreated. This guideline is published in NAMS' official journal, Menopause.
Clinical Guideline To Manage GSM in Women With Breast Cancer
Clinical Guideline To Manage GSM in Women With Breast Cancer

For survivors of breast cancer, not only is GSM more prevalent, but these women may experience its symptoms earlier because of cancer treatments. With the lack of data regarding the safety of vaginal hormone treatments and other alternatives for women with or at high risk for breast cancer, many have avoided using hormone treatments, and clinicians have often been reluctant to prescribe them.

Show Full Article


Left untreated, GSM can potentially adversely affect quality of life and partner relationships because of ongoing symptoms, including vulvovaginal dryness, burning, or irritation; painful intercourse; and recurrent urinary tract infections. It is estimated that more than 2 million survivors of breast cancer in the United States are affected by GSM, with most receiving no treatment.

The Consensus Panel of 16 experts created the consensus recommendations after a comprehensive, evidence-based review of existing literature. In addition, the Consensus Panel agreed that decision making regarding the type of treatment for GSM should be individualized and include balancing the risk of cancer recurrence with the severity of symptoms and effect on quality of life. The recommendations offer clinicians caring for this population of women some guidance regarding therapeutic decision making in the absence of clinical trial data.

"We want clinicians caring for this at-risk population to be armed with as much information as possible so that they can provide the best course of treatment for their patients," says Dr. JoAnn Pinkerton, executive director of NAMS. "Until additional studies are undertaken in this area, we are hopeful these consensus recommendations will provide added confidence for clinicians to move forward with treatment options that will provide relief to women from GSM symptoms."



Source: Eurekalert

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

Recommended Reading

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive